Mantle cell lymphoma (MCL) is one of the most aggressive B-cell lymphomas. While a number of protein-coding genes are altered, expression signature and importance of microRNA (miRNA) have not been well documented in this malignancy. Here, we performed miRNA expression profile in 30 patients with MCL using a platform containing 515 human miRNAs. Eighteen miRNAs were downregulated and 21 were upregulated in MCL when compared with normal B lymphocytes. The most frequently altered miRNAs are decrease of miR-29a/b/c, miR-142-3p/5p and miR-150 and increase of miR-124a and miR-155. Notably, expression levels of miR-29 family are associated with prognosis. The patients with significant downregulated miR-29 had short survival as compared to those who express relative high level of miR-29. Prognostic value of miR-29 is comparable with MIPI (MCL International Prognostic Index). Furthermore, we demonstrate miR-29 inhibition of CDK6 protein and mRNA levels by direct binding to 3'UTR. Inverse correlation between miR-29 and CDK6 was observed in MCL. Since cyclin D1 overexpression is a primary event and exerts its function through activation of CDK4/6, our results in primary MCL cells indicates that downregulation of miR-29 could cooperate with cyclin D1 in MCL pathogenesis.
Thus, our findings provide not only miRNA expression signature but also a novel prognostic marker and pathogenetic factor for this malignancy.
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INTRODUCTION
MCL constitutes approximately 5 to 10% of all non-Hodgkin's lymphomas 1 . Patients with MCL usually present with advanced disease. Chemotherapy in combination with monoclonal antibodies results in a short remission. Thus, MCL has the worst prognosis among non-Hodgkin's lymphoma subtypes with a median survival of approximately 3 years 2,3 . However, a subset of patients exhibit a more chronic course and may not require treatment for prolonged periods of time, suggesting that the biological mechanisms of this lymphoma could be more heterogeneous than initially thought 4 .
Given these poor clinical outcome and heterogeneity, many attempts have been made to identify genetic changes as prognostic markers and therapeutic targets for MCL. It has been shown that a blastic variant of MCL is associated with short survival 3 . High tumor cell proliferation due to INK4a and p53 alterations is also linked to shorter survival [5] [6] [7] .
The genetic hallmark of MCL is the t(11;14)(q13;q32) translocation that displaces the cyclin D1 gene on chromosome 11 downstream to the enhancer region of the IgH gene on chromosome 14 and causes its overexpression. While elevated level of cyclin D1 is found in virtually all cases, experimental evidence suggests that this event alone is insufficient to result in lymphoma and secondary genomic alterations are required. In fact, genetic studies in MCL revealed that gains of chromosome 3q and losses of 8p, 9p, 9q, 13q, and 17p identify patients with a more aggressive clinical evolution 8 . A number of candidate genes within these regions have been suggested to play a role in MCL pathogenesis.
MiRNA is a class of 22-nucleotide noncoding RNA, which is evolutionarily conserved. While they do not encode proteins, miRNAs are transcribed by RNA polymerase II as independent units in the nucleus. The primary transcript (pri-miRNA)
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From is processed by the nuclear RNaseIII Drosha and its cofactor DGCR8/Pasha to generate precursor miRNA (pre-miRNA). The pre-miRNA is rapidly exported to the cytoplasm by exportin-5 in a Ran-GTP-dependent manner, where is further processed by a second RNaseIII, Dicer, that cuts off the terminal loop and generates a mature ~22-nucleotide miRNA. The mature miRNA binds to the target mRNA 3'UTR and triggers either mRNA degradation or inhibition of translation, depending on degree of complementary between miRNA and its target 9, 10 . Accumulated studies have shown frequent deregulation of miRNAs in various human malignancies including various types of leukemia [11] [12] [13] , breast carcinoma 14, 15 , primary glioblastoma 16, 17 , lung cancer 18 , papillary thyroid carcinoma 19 , colon carcinoma 20 , pancreatic tumors 21, 22 and ovarian cancer 23 .
Deregulated miRNAs function as either oncogenes or tumor suppressors and some of them have been implicated in chemoresistance 23 , prognosis and tumor progression 24 while others can be used as diagnostic markers 25 .
In this report, we performed miRNA expression profile in malignant B-cells isolated from patients with MCL. Of 515 miRNAs analyzed, 18 were downregulated and 15 were upregulated. Notably, decrease expression levels of miR-29 family (miR-29a, miR-29b and miR-29c) are associated with short overall survival of patients with MCL.
Further, we demonstrated that miR-29 directly regulates CDK6. Inverse correlation between miR-29 and CDK6 was observed in MCL cell lines and primary tumor specimens. These findings indicate that deregulation of miRNA is a common event in MCL and that miR-29 could be a valuable prognostic marker and pathogenetic factor in MCL.
METHODS
Patients, tissue Collection and cell preparation
A total of 30 patients with MCL, treated at H. Lee Moffitt Cancer Center, were included in this study (approved by IRB). MCL diagnosis was made based on morphologic features, immunophenotype, cytogenetic and FISH findings and the presence of elevated cyclin D1. The following information was collected: age, gender, performance status, stages, number of extranodal sites involved, serum lactate dehydrogenase (LDH) level, the presence or absence of B symptoms, IPI and MIPI scores ( Table 1 ). Follow-up information was obtained from patients' medical records including response to initial chemotherapy and overall survival (OS). Survival analysis was applied only to the patients who have 36 month follow-up.
All MCL specimens were from lymph nodes except one from spleen. The characterization and purification of MCL samples were performed as described previously 26 . Briefly, the tissues were sliced into small pieces, gently dispersed and suspended into RPMI-1640 with 10% FBS. For preparation of viable, sterile, single cell suspensions, cells, obtained after low speed centrifugation, are re-suspended in media composed of 90% FBS and 10% DMSO either were frozen slowly or were first purified using a CD19 magnetic bead (Miltenyi Biotec, Auburn, CA). All frozen MCL cells had more than 85% purity and stored in liquid nitrogen for later analysis. Peripheral blood mononuclear cells (PBMCs) were obtained by Ficoll gradient centrifugation (ICN Biomedicals, Costa Mesa, CA) from five healthy donors and B lymphocytes were purified using a CD19 magnetic bead system (more than 90% purity) as normal control.
B-cell purity of >90% homogeneity was confirmed by three-color flow cytometry using markers CD19/CD3 and CD45.
MicroRNA microarray analysis
Total RNA was isolated using Trizol reagent (Invitrogen). MiRNA profiling was performed as previously described 23 . Briefly, miRNA array containg 515 human miRNAs was hybridized with [γ-32 P]ATP labeled small RNA probes. To ensure accuracy of the hybridizations, each labeled RNA sample was hybridized with three separate arrays and quantified. In addition, eight oligonuclotides with non-matching any known miRNA were used as hybridization controls. Hybridization signals for each spot of the array and background values at 15 empty spots were measured. The signals that fail to exceed the average background value by more than three standard deviations will be excluded. The data were normalized and unsupervised hierarchical clustering analysis with average linkage algorithms was performed with GeneCluster. The results were visualized with TreeView. Differentially expressed miRNAs were identified by using the t test procedure within significance analysis of microarrays (SAM), a method developed at Stanford University Labs 27 .
Plasmids
Expression plasmids of hsa-miR-29a, hsa-miR-29b and hsa-miR-29c were created by annealing self-complimentary oligonucleotides encompassing the sequence of mature miRNAs and cloned to the pcDNA 6.2-GW/EmGFP-miR vector (Block-IT; Invitrogen).
PmiR-Report-CDK6-1 and pmiR-Report-CDK6-2 were created by cloning CDK6 3'UTR 9129-9135bp and 9880-9886bp, which match seed sequence of miR-29, into downstream luciferase gene, respectively.
Their mutants (e.g., pmiR-Report-CDK6-1m and pmiR-Report-CDK6-2m) were obtained by mutation of the sequence matching seed sequence to indicated nucleotides (Fig. 4A ). The sequences used to create these For personal use only. on October 24, 2017. by guest www.bloodjournal.org From plasmids were shown in supplement Table 1 .
qRT-PCR
miRNA qRT-PCR was performed according to manufacturer's instruction (Applied Biosystem). PCR products also were analyzed by electrophoresis on a 12.5% polyacrylamide gel in 0.5 × Tris-borate EDTA and visualized by ethidium bromide staining. U6 was used as an internal control. Quantitative RT-PCR was performed for evaluation of CDK6 mRNA levels as previously described 28 and GAPDH severed as a loading control. The primers are seen in supplement Table 2 . immunohistochemistry and luciferase report were carried out as previously described 29 .
Knockdown of miR
Statistical Analysis. 
RESULTS

MiRNA expression profile in MCL
The characteristics of the MCL patients enrolled in this study are shown in Table 1 . The median follow-up time was 34.96 months. The average age of enrolled patients is 65 years old and most of these patients are male (95%). Eighty-five percent tumors were advanced stage at the time of diagnosis. All of the patients have received chemotherapy.
These features are consistent with previous studies 2,3 .
To identify miRNA expression signature in MCL, we performed miRNA microarray analysis in 30 patients with MCL and 5 normal healthy donors (e.g., CD19+ lymphocytes as controls). RNAs isolated from MCL cells and normal lymphocytes were hybridized to a customized miRNA microarray platform which contains 515 human miRNAs. The unsupervised hierarchical clustering revealed clearly distinctive expression patterns between MCL and normal lymphocytes ( Fig. 1A) . Overall, expression of 39 miRNAs was changed ≥ 1.5 fold in MCLs ( Table 2) We next asked whether the miRNA expression is associated with MCL prognosis. Of 30 MCL patients profiled, 24 had at least 36 months follow-up including the patients who died during this period time, 12 of which survive more than 3 years (good prognosis), and the others with overall survival ≤ comparing the miRNA expression profiles, we found distinct expression of several miRNAs between these 2 subgroups, which include upregulation of miR-155 and downregulation of miR-142-3p/5p and miR-29 family in poor prognosis patients (Fig.   1B ).
miRNA-29a/b/c expression levels are inversely associated with prognosis of MCL
To verify the miRNA microarray data and determine the prognostic value of these miRNAs, we performed qRT-PCR, using normal CD19-positive peripheral blood lymphocyte and lymph node as controls, and found that expression of miR-29 family members but not other miRNAs is closely associated with MCL prognosis (Fig. 2 and data not shown). While miR-29a/b/c were downregulated in both good and poor prognosis groups as compared to normal lymphocytes, they were more significantly reduced in the patients with poor prognosis, e.g., miR-29a/b/c levels are 2.0-fold below than those in the good prognosis group. However, combining 3 members of miR-29 did not increase statistical significance of between poor and good prognostic groups (Figs.
2A-C and S1).
Using mean relative expression level as a cutting value, we further analyzed the association between overall survival (OS) of MCL patients and miR-29 expression. A univariate Cox regression along with Kaplan-Meier estimate and log-rank tests revealed that MCL patients with relative higher level of miR-29a, miR-29b or miR-29c have much better OS than those whose tumors express lower level of miR-29 ( Fig. 3A-C) . Because miR-29a, miR-29b and miR-29c are exclusively co-deregulated in the MCL specimens examined, the combination of three members did not improve their prognostic value (Fig.  S1 ). Since international prognostic index (IPI) and mantle cell lymphoma international prognostic index (MIPI) have been used as predictors of MCL prognosis 30 , we further analyzed their prognostic value in the MCLs patients examined in this study and compared with that of miR-29. Consistent with previous study, MIPI is a better predictor than IPI (Figs. 3E and 3D) 30 . Notably, prognostic value of miR-29a/b/c is better than IPI and equivalent to MIPI (Fig. 3A-F ), suggesting that miR-29 could be valuable prognostic marker in MCL.
CDK6 is a direct target of miR-29
Since miR-29a/b/c are downregulated in majority of MCLs and the magnitude of their downregulation is associated with OS, we thought that miR-29 could play an important role in the pathogenesis of MCL. By searching databases RNA22 31 , DIANA 32 , picTAR 33 and Targetscan 34 , we found that 3'UTR CDK6 contains 2 sequence motifs (9129 -9135bp and 9880 -9886bp) that perfectly match with the "seed" sequence of miR-29 (Fig. 4A ). Both motifs are well conserved among human, mouse and rat (data not shown), suggesting a potential regulation of CDK6 by miR-29. To this end, we transfected Block-iT-miR-29a/b/c individually to Mino and HEK293T cells, which express low levels of miR-29 and high levels of CDK6 (Fig. 4B ). Cells transfected with Block-iT vector alone were used as control. Following selection with blasticidin, expression of transfected miR-29a/b/c was verified by qRT-PCR (Fig. 4C ). CDK6 protein and mRNA levels were assessed with immunoblotting and quantitative PCR. To further demonstrate miR-29 direct regulation of CDK6, we constructed luciferase reporters with two targeting sequences of wild-type (pmiR-CDK6-1-3'UTR and pmiR-CDK6-2-3'UTR) and mutated CDK6-3'UTRs ( Fig. 4A ). Both the wild-type and mutant reporters were introduced into Mino (miR-29-low) and Jeko-1 (miR-29-high) cells.
The luciferase activities of pmiR-CDK6-1-3'UTR and pmiR-CDK6-2-3'UTR were significantly suppressed in miR-29-high Jeko-1 but not in miR-29-low Mino cells.
However, pmiR-CDK6-3'UTR mutant, e.g., pmiR-CDK6-1m and pmiR-CDK6-2m, reporter activity had no difference between these 2 cell lines ( Fig. 6A ). Further, wild-type but mutated pmiR-CDK6-1-3'UTR and pmiR-CDK6-2-3'UTR were inhibited by expression of miR-29a, miR-29b, or miR-29c in HEK293T (( Fig. 6B) and Mino (Fig.   6C ) cells. In addition, treatment of Jeko-1 cell with poo1 2'O-me anti-miR-29a/b/c oligonucleotides increased reporter activity of pmiR-CDK6-1-3'UTR and pmiR-CDK6-2-3'UTR ( Fig. 6D ). Taken collectively, these data indicate that CDK6 is a direct target of miR-29 family. (Fig. 7B ). In addition, miRNA-LNA in situ hybridization and immunohistochemical staining showed inverse expression of miR-29 and CDK6 (Fig. S5 ). These findings demonstrate miR-29 regulation of CDK6 in vivo and frequent overexpression of CDK6 in MCL.
Downregulation of miR-29 results in frequent overexpression of CDK6 in MCL
DISCUSSION
While deregulation of individual miRNA has been reported in MCL [35] [36] [37] , miRNA expression profile has not been documented in this malignancy. In this study, we have (Table 2) .
However, among the five most commonly altered miRNAs (miR-150, miR-142-3p/5p, miR-29a/b/c, miR-124a and miR-155), only miR-124a locus was found to be amplified in the genomic array analysis, suggesting that deregulation of other miRNAs could occur at transcriptional or/and post-transcriptional levels.
The clinical course of MCL is highly variable. Some patients survive less than 6 months, whereas others live more than 10 years. 30 . In addition, the relationship between MCL prognosis and the gene expression profiles have been explored using genome-scale expression profiles assessed by cDNA microarrays 39 and qRT-PCR analysis of the expression of 39 genes with potential prognostic and pathogenetic impact in MCL 39 . In this study, we have shown that miR-29, while is downregulated in near all MCLs, expression levels of miR-29 are inversely correlated with OS of MCLs. Its prognostic value is comparable with MIPI.
In accordance with our findings, miR-29 family has recently been shown as a prognostic marker in B cell chronic lymphocytic leukemia (CLL) 40 .
Overexpression of cyclin D1 is present in nearly all cases of MCL, which is thought to be primary event by facilitating G1-S cell cycle progression. This action requires cyclin D1 binding to CDK4 and CDK6, which phosphorylate and inactivate RB1, leading to the release of E2F transcription factors and the subsequent progression of the cell into S phase. While miR-29 did not regulate cyclin D1 and CDK4 (data not shown), we demonstrated that CDK6 is a direct target of miR29 and that downregulation of miR-29a/b/c results in upregulation of CDK6 in MCL. The elevated CDK6 cooperates with cyclin D1 to further promote cell cycle progression. In addition, miR-29 has been shown to negatively regulate several other important genes including oncogenes Tcl-1 41 and Mcl-1 42 , and cell growth and survival genes, YY1 43 , p85α, CDC42 44 and DNMT3 45 as well as natural killer and T cell inhibitor B7-H3 46 . We have also shown that ectopic expression of miR-29c significantly reduces Mino cell growth, whereas knockdown of miR-29 family enhances Jeko-1 cell proliferation (Fig. S6 ).
As described above, miR-29 was also frequently downregulated in CLL 40 as well as other solid tumors 43, 45 .
Expression of miR-29 represses the tumor cell growth 43, 45 . Therefore, we concluded that miR-29 family is a tumor suppressor miRNA and that downregulation of miR-29 could play a pivotal role in pathogenesis of MCL (Fig. 7C ), CLL and other malignancies by negative regulation of its targets including CDK6. The biological effects of miR-29 on different organs could be further addressed by creation of knockout mouse.
In summary, we have identified miRNA expression signature and frequent deregulation of a set of miRNAs (e.g., miR-150, miR-142-3p/5p, miR-29a/b/c, miR-124a
and miR-155) in MCL. Particularly, downregulation of miR-29 could be a potential molecular marker to discriminate MCLs into good and poor prognostic subgroups. For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Conflict-of-interest disclosure: The authors declare no competing financial interests.
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